logo
Hepatitis C - Class Actions Settlement
HomeSearchContact UsFrançaisPrivacy

Claimants:
Essential Information
Claimants:
Additional Information
Claimants:
Loss of Income / Loss of Support / Loss of Services
Periodic Re-Assessment by the Courts
Appeals
Documents
Forms
Contacts and Links
Annual Reports
Administrator


2001 Annual Report

Important Notice!

At the end of Year One, Annual Reports and Schedules were submitted by all Court appointed service providers and reviewed by the Courts having jurisdiction over the 1986-1990 Hepatitis C Settlement Agreement. This section of the web site includes all Annual Reports and Schedules. Please note that some Schedules have been modified because the original version contains commercially confidential information.


I. Year 1 (December 1, 1999 to March 31, 2001) Annual Report of the Joint Committee
  Overview and Summary
    Schedule A
   
General
   
Deloitte & Touche
   
Schedule B
Schedule C
Schedule D
Schedule E
Schedule F
Schedule G
Schedule H
   
Royal Trust
   
Schedule I
 
TD Asset Management
    Schedule J
 
Towers Perrin
    Schedule K
Schedule L
   
 
Eckler Partners Ltd.
   
Schedule M
Schedule N
Schedule O
 
Canadian Blood Services
    Schedule P
Schedule Q
 
Crawford/Garden City Group Canada
   
Schedule R
Schedule S
Schedule T
 
Fund Counsel
    Schedule U
   
Joint Committee
   
Schedule V
 
II. Financial Statements Prepared by the Court Appointed Auditors - Deloitte and Touche
  Auditors' Report for Year 1
Schedule A – Financial Statements
Notes to the Financial Statements
 
III. Canadian Blood Services Expenses for Year 1
  Auditors' Notes to the Joint Committee of the 1986 - 1990 Hepatitis C Fund
Schedule D – Expenses For the One-Year Period Ended March 31, 2001
 

IV. Héma Québec Expenses for Year 1
  Auditors' Notes to the Joint Committee of the 1986 - 1990 Hepatitis C Fund
Schedule E – Expenses For the Period up to March 31, 2001
 

V. The Administrator's Expenses and Annual Report for Year 1
  Claims Activity – Statistical Summary
Milestones
Auditors' Notes to the Joint Committee of the 1986 - 1990 Hepatitis C Fund

 
 

Disclaimer